english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Protecting patients: France's Transparency Committee steps in

As evidenced by Prescrire's annual update of drugs to avoid in the name of better patient care, many drugs remain authorised for years despite an unfavourable harm-benefit balance. How then can patients and community resources be protected?
1 March 2020

Painful endometriosis: initial treatment options

In the absence of urinary or intestinal symptoms, and if the patient is not planning to become pregnant any time soon, first try analgesics such as NSAIDs or paracetamol. Hormonal contraception or a levonorgestrel intrauterine device are other options.
1 March 2020

Rotarix° oral vaccine: wrong-route errors

The Rotarix° oral vaccine applicator has a deceptive syringe-like appearance, which has resulted in intramuscular injections being given in error.
1 March 2020

Drugs to avoid in the name of better patient care: 2020 update

Drugs to avoidThe independent French medical journal Prescrire's annual review of drugs to avoid includes documented cases of 105 drugs authorised in the European Union that are more dangerous than beneficial. The aim is to make it easier to choose safe, effective treatments, primarily to avoid exposing patients to unacceptable harms.
1 February 2020

Annual Prescrire Drug Awards announced in Paris: 6 winning drugs, but no "Pilule d'Or"

Prescrire Drug Award The independent French medical journal Prescrire announced its Drug Awards for 2019, at its yearly awards ceremony in Paris on 30 January. Three drugs made the "Honours List" and three others were recognised as "Noteworthy", but there was no "Pilule d'Or" (Golden Pill) awarded this year.
1 February 2020

The Prescrire Packaging Awards for 2019: one winner and plenty of losers

Prescrire Drug Packaging Awards The independent French medical journal Prescrire held its annual awards ceremony in Paris on 30 January. A Prescrire Packaging Award recognised Isentress° granules for oral suspension (raltegravir) for its clear, informative instruction booklet, whereas 34 "Red Cards" were handed out for substandard or dangerous packaging.
1 February 2020

Prescrire's Information Awards for 2019: just 6 drug companies (out of 112 contacted) are honoured for the quality of information provided

Prescrire Drug Information Award Prescrire's annual Information Awards recognise drug companies which respond to Prescrire's requests with complete and relevant information. In 2019, only a half-dozen drug companies (out of 112 companies contacted by Prescrire's editors with information requests) embraced transparency, in the best interest of patients.
1 February 2020

Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption

FEATURED REVIEW The GABA analogue baclofen (Baclocur°, Ethypharm), used since the 1970s as a muscle relaxant, has now been granted marketing authorisation in France for the reduction of alcohol consumption in alcohol-dependent patients in whom the other drug treatments have failed. What is known about baclofen's harm-benefit balance in this clinical situation as of late 2019?
Full review (4 pages) available for download by subscribers.
1 February 2020

In the February issue of Prescrire International - High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

FREE DOWNLOAD In the Adverse Effects section this month: should patients taking a direct oral anticoagulant switch to a vitamin K agonist such as warfarin, in light of the French drug regulatory agency's recent advisory?
Full text available for free download.
1 February 2020

SSRI antidepressants: persistant sexual dysfunction

Antidepressants known as selective serotonin reuptake inhibitors (SSRIs) expose patients to sexual adverse effects that may persist long after discontinuation of the drug.
1 February 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90